Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aileron Therapeutics Inc (NQ: ALRN )

2.120 +0.200 (+10.42%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 108,704
Open 1.950
Bid (Size) 2.090 (1)
Ask (Size) 2.130 (1)
Prev. Close 1.920
Today's Range 1.930 - 2.150
52wk Range 1.010 - 3.300
Shares Outstanding 4,541,167
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga

Performance

YTD
-33.75%
-33.75%
1 Month
+81.20%
+81.20%
3 Month
+27.71%
+27.71%
6 Month
+44.22%
+44.22%
1 Year
-23.47%
-23.47%

More News

Read More
Top 5 Health Care Stocks That May Collapse In Q2
Via Benzinga
Looking Into Aileron Therapeutics's Recent Short Interest
Via Benzinga
S&P 500 Down 2%; Mobilicom Shares Spike Higher
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Aileron Therapeutics Shelves Development On Chemoprotection Agent, Shares Fall
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Tumbles More Than 500 Points; US Manufacturing PMI Rises In February
Via Benzinga
Nasdaq Drops Over 100 Points; Walmart Issues Cautious Forecast
Via Benzinga
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022
From Aileron Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Vintage Wine Estates Shares Tumbled 40%; Here Are 70 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why CinCor Pharma Is Trading Higher By 63%, Here Are 79 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why Is Marker Therapeutics Trading Higher By 119%: Here Are 42 Stocks Moving Premarket
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.